MedTrace Logo

Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria

NCT00907374 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2012-03-30

Study results available
· View outcomes & findings →

Summary

The objective of the study is to assess the effect of standard versus aggressive inhibition of the renin-angiotensin system (RAS)in type 2 diabetic patients with microalbuminuria (MA) on; a)progression of microalbuminuria, b)estimated glomerular filtration rate (eGFR), c)endothelial dysfunction (measured by post-hyperemia arterial tonometry) and d)the slowing of the progression of atherosclerotic disease (measured by carotid intima media thickness \[CIMT\]).

Conditions

  • Microalbuminuria

Interventions

DRUG

benazepril

benazepril 10 mg orally once daily

DRUG

benazepril

40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily

Sponsors & Collaborators

  • Charles Drew University of Medicine and Science

    lead OTHER

Principal Investigators

  • Naureen Taureen, MD · Charles Drew University

  • Mayer B. Davidson, MD · Charles Drew University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00907374 on ClinicalTrials.gov